“So transfer of the gene to allow the good gene to be expressed. But in the future, we are also considering to use proteins that are encoded with the good gene as a kind of drug that can be administered to the patient.”
Dr. Madeddu says human trials could begin in about two years. Find the full interview at www.maryfurlong.com/podcasts.
You can find us at Techstination.com. I’m Fred Fishkin.
| Categories: | General Technology News |
|---|